Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $120.80

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $120.80.

A number of equities research analysts have recently weighed in on ORKA shares. HC Wainwright raised their price objective on shares of Oruka Therapeutics from $75.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. UBS Group raised their price objective on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the company a “buy” rating in a report on Monday, April 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Finally, BTIG Research restated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday.

Insiders Place Their Bets

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Friday, May 15th. The stock was sold at an average price of $61.85, for a total transaction of $432,950.00. Following the sale, the insider owned 33,377 shares in the company, valued at $2,064,367.45. This represents a 17.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 30,765 shares of company stock worth $1,522,695 over the last 90 days. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its stake in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics during the 4th quarter worth $37,000. PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics during the 3rd quarter worth $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in Oruka Therapeutics during the 4th quarter worth $67,000. Finally, Russell Investments Group Ltd. acquired a new stake in Oruka Therapeutics during the 3rd quarter worth $43,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Down 3.1%

Oruka Therapeutics stock opened at $61.93 on Monday. The firm has a market cap of $3.73 billion, a PE ratio of -31.92 and a beta of -0.20. Oruka Therapeutics has a 52-week low of $9.40 and a 52-week high of $91.00. The company’s 50 day moving average is $55.17 and its two-hundred day moving average is $39.33.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, equities research analysts anticipate that Oruka Therapeutics will post -2.2 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.